Celularity

About:

Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies.

Website: https://www.celularity.com

Twitter/X: celularity

Top Investors: Alumni Ventures, Human Longevity, Section 32, Heritage Group, Castor Ventures

Description:

Celularity is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

Total Funding Amount:

$400M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Florham Park, New Jersey, United States

Founded Date:

2017-09-01

Contact Email:

media(AT)celularity.com

Founders:

Andrew L. Pecora, Peter Diamandis, Robert J. Hariri

Number of Employees:

101-250

Last Funding Date:

2022-05-26

IPO Status:

Public

© 2025 bioDAO.ai